Faron Pharmaceuticals Oy has announced that it will host a virtual call for investors to discuss new data from the Phase I/II BEXMAB study of its investigational immunotherapy, Bexmarilimab, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The call will take place on October 11 and will provide an update on the most recent data from the study, which involved weekly dosing of Bexmarilimab in leukemia patients. The webcast will also include a Q&A session. Investors can register for the webcast on the company's website or contact the investor relations team for more information.
Bexmarilimab is a novel anti-Clever-1 humanized antibody that targets myeloid cell function and aims to overcome resistance to existing treatments in cancer patients. By binding to the Clever-1 receptor on macrophages, Bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive state to an immunostimulatory one. This leads to the upregulation of interferon production and primes the immune system to attack tumors, as well as sensitizing cancer cells to standard care treatments.
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing macrophage re-programming therapies for effective cancer immunotherapies. Its lead asset is Bexmarilimab, which is currently being investigated in a Phase I/II clinical trial for hematological cancers in combination with other standard treatments. The company's mission is to bring the promise of immunotherapy to a broader population by harnessing the power of the immune system.
The company cautions that forward-looking statements in this announcement are subject to various factors that could cause actual results to differ materially from expectations. These factors include the ability to successfully license programs, economic and business conditions, competition, regulatory changes, and availability of funding, among others. The company does not undertake any obligation to publicly update or revise forward-looking statements.